Browser does not support script.
Skip to main content
Responding to the decision by the National Institute for Health and Clinical Excellence (NICE) not to recommend Erlotinib as a treatment for non-small-cell lung cancer, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'This is very disappointing news, particularly as lung cancer has one of the lowest survival outcomes of any cancer .
'Every cancer patient should get the drugs their doctor recommends, regardless of what type of cancer they have, or where they live. It is unacceptable this isn’t always happening at present.
'To ensure all cancer patients get better access to treatments, it is vital that this cancer drug and those for rarer cancers  are placed on the priority list of the Government’s Cancer Drugs Fund.'
If you have any questions about Macmillan we would love to hear from you| .
You can also follow us| on Facebook, Twitter, Flickr or YouTube.
© Macmillan Cancer Support 2013
what are these?|